Every 8-K that Catalyst Pharmaceutical Inc. (CPRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CPRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CPRX filings page.
Catalyst Pharmaceuticals completed its merger with Angelini Pharma on July 15, 2026, when Angelini subsidiary Angelini Cielo merged with and into Catalyst, which continues as a wholly owned subsidiary of Angelini Pharma.
At the effective time, each share of Catalyst common stock was converted into the right to receive $31.50 in cash per share, without interest and subject to tax withholding. Catalyst notified Nasdaq of the merger, requested delisting, and trading in its stock will be suspended on July 16, 2026, followed by deregistration and termination of SEC reporting obligations. All pre-merger directors resigned and Angelini designees joined the board, and the company’s certificate of incorporation and bylaws were amended and restated as provided in the Merger Agreement.
Catalyst Pharmaceuticals reported that its stockholders approved the planned merger with Angelini Pharma, under which Catalyst will become a wholly owned subsidiary of Angelini. The merger proposal received 97,340,180 votes for, 1,143,815 against and 242,616 abstentions, satisfying a key closing condition in the Merger Agreement.
At the special meeting, 98,726,611 shares, or about 80.6% of the 122,417,458 shares outstanding as of the record date, were represented. Stockholders did not approve, on a non-binding advisory basis, the merger-related executive compensation proposal, but this does not affect completion of the merger. All current directors have indicated they will resign at the effective time of the merger.
Catalyst Pharmaceuticals reported topline results from a two-part Phase 1 clinical study of AGAMREE (vamorolone) in healthy adult volunteers. The study showed balanced corticosteroid activity, with expected cortisol suppression and no evidence of significant immunosuppressive activity at clinical doses.
In Part A, vamorolone produced similar cortisol suppression to deflazacort at label-based clinical doses, supporting currently labeled dosing for Duchenne muscular dystrophy. In Part B, even at an ascending dose up to 40 mg/kg/day, which is above currently approved dosing, the data did not indicate clinically meaningful immunosuppression, reinforcing its potential use across a broad range of chronic inflammatory rare diseases.
Catalyst Pharmaceuticals, Inc. reports that the U.S. Federal Trade Commission granted early termination of the Hart-Scott-Rodino antitrust waiting period for its planned acquisition by Angelini Pharma. The merger agreement was signed on May 6, 2026, and Catalyst will become a wholly owned subsidiary of Angelini Pharma if completed.
The transaction still requires adoption of the merger agreement by holders of at least a majority of Catalyst’s outstanding common shares and other customary closing conditions. The parties currently expect the deal to close in the third quarter of 2026, as described in Catalyst’s definitive proxy statement filed with the SEC on June 8, 2026.
Catalyst Pharmaceuticals reported first quarter 2026 total revenues of $149.4 million, up 5.6% from $141.4 million a year earlier, driven by growth in key rare-disease drugs. Net product revenue from FIRDAPSE rose 18.1% to $98.9 million and AGAMREE revenue jumped 66.6% to $36.7 million, while FYCOMPA declined 61.3% to $13.8 million.
GAAP net income increased to $63.7 million ($0.50 diluted per share), with non-GAAP net income of $100.3 million ($0.79 diluted per share), reflecting margin expansion and lower cost of sales. Cash and cash equivalents reached $755.9 million with no funded debt as of March 31, 2026. The company stated it will not provide forward-looking guidance or host an earnings call for this quarter.
Catalyst Pharmaceuticals agreed to be acquired by Angelini Pharma in an all-cash deal. Angelini will buy all outstanding Catalyst shares for $31.50 per share, valuing the company at approximately $4.1 billion, a 21% premium to Catalyst’s unaffected April 22, 2026 closing price and a 28% premium to its 30-day average.
A wholly owned Angelini subsidiary will merge into Catalyst, which will become a private, wholly owned subsidiary. The transaction has been unanimously approved by both boards and is expected to close in the third quarter of 2026, subject to a stockholder vote, antitrust clearance and other customary conditions. The merger has no financing condition, with Angelini planning to use cash and debt.
The merger agreement includes a termination fee of about $155.5 million payable by Catalyst to Angelini in specified circumstances, including acceptance of a superior proposal. Catalyst’s directors and executive officers signed voting agreements to support the deal. Separately, Catalyst and SERB settled patent litigation with Hetero over generic FIRDAPSE®, with Hetero barred from U.S. sales of its generic before January 2035, resolving all pending FIRDAPSE patent cases.
Catalyst Pharmaceuticals, Inc. filed an amended current report to correct a scrivener’s error in the signature date of a previously submitted report. No other changes were made.
The company also notes that a federal court in New Jersey has delayed the start of a bench trial with Hetero USA, Inc. concerning the validity of its Orange Book-listed FIRDAPSE® patents, which expire in 2032, 2034, and 2037, moving the trial start from March 23, 2026 to May 18, 2026.
Catalyst Pharmaceuticals, Inc. reports that a federal court has postponed the start of its pending patent bench trial against Hetero USA, Inc. The District Court for the District of New Jersey rescheduled the trial from March 23, 2026 to May 18, 2026.
The case concerns the validity of Catalyst’s Orange Book-listed patents covering FIRDAPSE, which currently expire in 2032, 2034, and 2037. The filing does not change the claims themselves, but indicates the timetable for resolving this patent dispute has been extended by nearly two months.
Catalyst Pharmaceuticals reported record 2025 results, with total revenues of $589.0 million, up 19.8% year over year, and GAAP net income of $214.3 million. Growth was led by FIRDAPSE product revenue of $358.4 million, up 17.1%, and AGAMREE revenue of $117.1 million, up 154.3%, while FYCOMPA revenue declined 17.4% to $113.3 million as generics entered the market.
Cash and cash equivalents rose to $709.2 million as of December 31, 2025, helped by strong profitability, partially offset by $25.3 million of share repurchases. For 2026, the company guides total revenues to $615–$645 million, with higher expected sales from both FIRDAPSE and AGAMREE and a sharply lower FIRDAPSE U.S. royalty burden, as the overall upstream rate drops to 6% beginning January 26, 2026.
Catalyst Pharmaceuticals, Inc. reported that it will present at the 44th Annual JP Morgan Healthcare Conference on January 12, 2026. The company has made its conference slide presentation available as Exhibit 99.1 to this report and incorporates it by reference. The disclosure is furnished under Regulation FD, meaning it is not treated as filed for liability purposes or automatically included in other securities law filings. The company also highlights that the report and presentation contain forward-looking statements and directs readers to its Form 10-K for the year ended December 31, 2024 and subsequent SEC reports for a discussion of risks that could cause actual results to differ.
Catalyst Pharmaceuticals (CPRX) reported that it issued a press release on November 5, 2025 announcing results for the three and nine months ended September 30, 2025, along with a business update. The press release is furnished as Exhibit 99.1. This routine update signals that quarterly and year-to-date performance details are available via the attached exhibit, which also serves as the company’s formal communication of its latest operating highlights.
Catalyst Pharmaceuticals, Inc. disclosed that its Board of Directors has approved a share repurchase program authorizing the company to buy back up to $200 million of its common stock. The program runs from October 1, 2025 through December 31, 2026.
The company may repurchase shares through methods such as open market purchases or privately negotiated transactions. The timing and amount of any repurchases will depend on factors including stock price, business and market conditions, regulatory requirements, and alternative investment or acquisition opportunities. Catalyst plans to use existing cash on hand to fund the program, is not obligated to repurchase any specific amount, and may suspend or terminate the program at any time.
Catalyst Pharmaceuticals filed an amended current report to correct a naming error in an earlier update about a patent litigation settlement related to its FIRDAPSE® patents. The company had reported a prior settlement with “Inventia Life Science Pty Ltd,” but clarified that the correct party is Inventia Healthcare Limited.
The amendment states that no other terms of the previously disclosed settlement with Lupin or the related press release were changed. Catalyst attached the corrected August 26, 2025 press release as an exhibit, confirming that the update is purely to fix the identity of the earlier settling party.
Catalyst Pharmaceuticals, Inc. has entered into a settlement agreement with Lupin Ltd. and Lupin Pharmaceuticals, Inc. over patent litigation related to a proposed generic version of FIRDAPSE (amifampridine) 10 mg tablets. Under the agreement, Lupin will not market its generic FIRDAPSE in the United States any earlier than February 25, 2035, if it receives U.S. Food and Drug Administration approval, except in certain limited customary circumstances. All ongoing FIRDAPSE patent litigation between Catalyst, its licensor SERB S.A., and Lupin in the U.S. District Court for the District of New Jersey will be terminated. Catalyst notes that separate FIRDAPSE patent litigation against Hetero covering all Orange Book-listed patents remains ongoing, and there is no assurance that a generic version will be kept off the U.S. market until February 25, 2035.